| DIRECT COMPETITOR COMPARISON | |
| KNDL | CVD | PRXL | Pvt1 | Industry | | Market Cap: | 229.32M | 3.41B | 722.24M | N/A | 161.24M | | Employees: | 4,275 | 8,826 | 9,275 | 21,0001 | 95 | | Qtrly Rev Growth (yoy): | -26.10% | 5.60% | -3.80% | N/A | 20.50% | | Revenue (ttm): | 582.27M | 1.92B | 1.23B | 2.70B1 | 46.74M | | Gross Margin (ttm): | 35.45% | 30.66% | 30.52% | N/A | 68.58% | | EBITDA (ttm): | 63.06M | 324.37M | 127.16M | N/A | -7.12M | | Oper Margins (ttm): | 8.23% | 12.45% | 5.84% | N/A | 2.25% | | Net Income (ttm): | 22.51M | 180.02M | 38.13M | N/A | N/A | | EPS (ttm): | 1.502 | 2.808 | 0.659 | N/A | -0.17 | | P/E (ttm): | 10.26 | 18.98 | 18.85 | N/A | 17.12 | | PEG (5 yr expected): | 0.64 | 1.49 | 0.99 | N/A | 1.04 | | P/S (ttm): | 0.40 | 1.80 | 0.60 | N/A | 4.17 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | CVD | | We Expect Ailing CROs to Recover
Wed, Nov 25 -
Morningstar.com | | • | CVD | | China Biotech Week in Review: CROs Consolidating
Sun, Nov 22 -
at Seeking Alpha | | • | CVD | | The Stockpickers: Fund managers hunt small-caps that can grow bigger
Fri, Nov 20 -
at MarketWatch | | • | CVD | | Zacks #5 Rank Additions for Friday
Fri, Nov 20 -
Zacks.com | | • | CVD | | Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
Wed, Nov 18 -
PR Newswire | | • | CVD | | Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
Wed, Nov 18 -
PR Newswire | | • | PRXL | | PAREXEL Experts to Discuss Impact of Pharmacovigilance Trends on Biosimilars and Generics at World Generic Medicines Congress Americas
Wed, Nov 18 -
PR Newswire | | • | PRXL | | Perceptive Informatics Expands Nuclear Imaging Capabilities for Cardiology Trials
Tue, Nov 17 -
PR Newswire | | • | PRXL | | PAREXEL Experts to Discuss Global Capabilities to Meet Urgent Demand For Cardiovascular Treatments at AHA Scientific Sessions
Mon, Nov 16 -
PR Newswire | | • | CVD | | How Do You Say 'Drug Development' in Mandarin?
Thu, Nov 12 -
at Motley Fool | | • | PRXL | | PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Change in Directors or Principal Officers
Thu, Nov 12 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
